-
Hand\\ng editor 1 ore K Kvien ' Department ot Medicine,
Uni'lersit)' of Auckland, Auckland, New Zealand 2Department of
Medidne, Uni'lersit)' of Otago, Christchurch, New Zealand
Correspondence to Dr Nicola Dalbeth, Department of Medicine,
University of
Auckland~ Private Bag 92019, 85 Park Road, Grafton, Auckland
1023, New Zealand; [email protected]
Received 27 January 2014 Revised 18 March 2014 Accepted 20 March
2014 Published Online First 9 April2014
Hyperuricaemia and gout: time for a new stagirlg system? Nko\a
Dalbeth, 1 Lisa Stamp2
ABSTRACT The current widely used clinical staging system for
hyperuricaemia and gout describes the symptomatology of gout, but
does not capture key aspects of the pathological basis of the
disease. We propose a new clinical staging system. Stage A:
hyperuricaemia, but without evidence of monosodium urate (MSU)
crystal deposition or symptoms of gout. Stage B: MSU crystal
deposition by microscopy or advanced imaging, but without signs or
symptoms of gout. Stage C: MSU crystal deposition with prior or
current symptoms of acute gout flares. Stage D: advanced gout
requiring specialist interventions. This proposed new staging ~em
provides a clear focus on gout as a chronic disease of MSU crystal
deposition, and provides a rational framework to test the role of
screening and treatment of asymptomatiG ,disease.
-
Receivl!d evjsed 18 Matth R red 20 Matd12014 ~onllne first
9 Aprf1 2014
CrossMark
To cite: Dalbeth N, Stamp L. Ann Rheum Dis
2014;73:1598-1600.
1598
-~ . , - """ t"''V'fiUC~ Q
rational framework to test the role of screening and treatment
of asymptomatic;; disease.
-
~te. ... ~ut;y. ar.thritis: -sustained hyperurkaemia .. leads to
the ~~~t19g_,_g(
MSD..,~~ll)J@:l~Qt..p~riarricular...tissues,resu.lt;rxg m ~.
intennittent..self .. limiting -aeute~inflammat0ry. atitht:itis:
..
..... t.;J'!Jcnt:~l ~ut: define~- a the . p,eriQd between acut~
~tracks . . ~e individual wilr~~~~ }1;~~~i-i~e~i~ ~drh~~ :urther
attacks without treatment.
thaf'.Ki!S'UCiysta'fs' are'prese'D:r-m"many
'P'e8p1'e'Willt...,.Hfper:c.u'itaec ~~W,tbJl.Q.,.hl~ocy,. .of
.flares andno ,dinical.evidencef tophi. These individuals are not
captured within the current staging system.
Simil~~J.n,gegplt;.-i.th, ,grior.~~t(1,/J~t~~ !W~hY.J?.P.~i_;:
~~Jlliii,-MSU.q:.ystals~ma~ be---present-.,microscopiGaily....a~.
joll}ts-t.P~t"'aEe-.notmelinieallr-:inflamed-..and i.n...i9in!$ ..
tJl~t ,?_ay~ -~-evef. been...._aff6cted.:.by-flares:t27 These
patients may have i~~a:sing ..,. C1:~n;~top.1trtce.1Ytts;
g.o.ttt\.usually occurs after gout has been
pr'esent for ffi
-
10 McGill synovial
11 Grassi W, gout and 2006;36:
12 Choi HK.
13
17
18
19
-
Contributors Both authors conceived of the paper and drafted the
manuscript. Funding NO and LS are supported b th H I h (grant
numbers 10/414 and 12/1 11 ). y e eat Research Council of New
Zealand Competing interests ND has ~ 'ved . Savi~nt, Menorini,
AstraZeneca, Ar~e~ N con~ultmg or speaker fees from Takeda,
recetved consulting fees from AstraZen~ca~artts, Metabolex and
Fonterra. LS has Provenance and peer review N .
at commlsstoned; externally peer reviewed.
REFERENCES t McCarty DJ, Hollander JL Id 'f' . ~~---J . ._ ~
~--- . entt ICatton of urate rn.rtals 't
,. Y;) n aouru \ll\n\d.al fluiri
measurement 25 Klippel J. Prim
2001. 26 Pascual E. Pet
the synovial i 27 Bomalaski JS
knee joints o 1986;29:141
28 Lindsay K. a study of~ J Clin Rhe
29 Harrold l and treat (Oxford)
30 Hunt SA, Manage the Pr